The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making

Thomas Van den Broeck; Steven Joniau; Liesbeth Clinckemalie; Christine Helsen; Stefan Prekovic; Lien Spans; Lorenzo Tosco; Hendrik Van Poppel; Frank Claessens

doi:10.1155/2014/627510

The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making

Thomas Van den Broeck, Steven Joniau, Liesbeth Clinckemalie, Christine Helsen, Stefan Prekovic, Lien Spans, Lorenzo Tosco, Hendrik Van Poppel, Frank Claessens

Research output: Contribution to journal › Review article › peer-review

Abstract

Prostate cancer (PCa) is a major health care problem because of its high prevalence, health-related costs, and mortality. Epidemiological studies have suggested an important role of genetics in PCa development. Because of this, an increasing number of single nucleotide polymorphisms (SNPs) had been suggested to be implicated in the development and progression of PCa. While individual SNPs are only moderately associated with PCa risk, in combination, they have a stronger, dose-dependent association, currently explaining 30% of PCa familial risk. This review aims to give a brief overview of studies in which the possible role of genetic variants was investigated in clinical settings. We will highlight the major research questions in the translation of SNP identification into clinical practice.

Original language	English
Article number	627510
Journal	BioMed Research International
Volume	2014
DOIs	https://doi.org/10.1155/2014/627510
Publication status	Published - 2014
Externally published	Yes

Keywords

Decision Making
Humans
Male
Polymorphism, Single Nucleotide
Prostatic Neoplasms/diagnosis
Risk Factors

Access to Document

10.1155/2014/627510

Cite this

@article{e33f42daaf0e43a5a7a06248f9f24427,

title = "The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making",

abstract = "Prostate cancer (PCa) is a major health care problem because of its high prevalence, health-related costs, and mortality. Epidemiological studies have suggested an important role of genetics in PCa development. Because of this, an increasing number of single nucleotide polymorphisms (SNPs) had been suggested to be implicated in the development and progression of PCa. While individual SNPs are only moderately associated with PCa risk, in combination, they have a stronger, dose-dependent association, currently explaining 30% of PCa familial risk. This review aims to give a brief overview of studies in which the possible role of genetic variants was investigated in clinical settings. We will highlight the major research questions in the translation of SNP identification into clinical practice.",

keywords = "Decision Making, Humans, Male, Polymorphism, Single Nucleotide, Prostatic Neoplasms/diagnosis, Risk Factors",

author = "{Van den Broeck}, Thomas and Steven Joniau and Liesbeth Clinckemalie and Christine Helsen and Stefan Prekovic and Lien Spans and Lorenzo Tosco and {Van Poppel}, Hendrik and Frank Claessens",

year = "2014",

doi = "10.1155/2014/627510",

language = "English",

volume = "2014",

journal = "BioMed Research International",

issn = "2314-6141",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making

AU - Van den Broeck, Thomas

AU - Joniau, Steven

AU - Clinckemalie, Liesbeth

AU - Helsen, Christine

AU - Prekovic, Stefan

AU - Spans, Lien

AU - Tosco, Lorenzo

AU - Van Poppel, Hendrik

AU - Claessens, Frank

PY - 2014

Y1 - 2014

N2 - Prostate cancer (PCa) is a major health care problem because of its high prevalence, health-related costs, and mortality. Epidemiological studies have suggested an important role of genetics in PCa development. Because of this, an increasing number of single nucleotide polymorphisms (SNPs) had been suggested to be implicated in the development and progression of PCa. While individual SNPs are only moderately associated with PCa risk, in combination, they have a stronger, dose-dependent association, currently explaining 30% of PCa familial risk. This review aims to give a brief overview of studies in which the possible role of genetic variants was investigated in clinical settings. We will highlight the major research questions in the translation of SNP identification into clinical practice.

AB - Prostate cancer (PCa) is a major health care problem because of its high prevalence, health-related costs, and mortality. Epidemiological studies have suggested an important role of genetics in PCa development. Because of this, an increasing number of single nucleotide polymorphisms (SNPs) had been suggested to be implicated in the development and progression of PCa. While individual SNPs are only moderately associated with PCa risk, in combination, they have a stronger, dose-dependent association, currently explaining 30% of PCa familial risk. This review aims to give a brief overview of studies in which the possible role of genetic variants was investigated in clinical settings. We will highlight the major research questions in the translation of SNP identification into clinical practice.

KW - Decision Making

KW - Humans

KW - Male

KW - Polymorphism, Single Nucleotide

KW - Prostatic Neoplasms/diagnosis

KW - Risk Factors

U2 - 10.1155/2014/627510

DO - 10.1155/2014/627510

M3 - Review article

C2 - 24701578

SN - 2314-6141

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

M1 - 627510

ER -

The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making

Abstract

Keywords

Access to Document

Fingerprint

Cite this